News

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

  • SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 9:45 a.m. EDT.
    08/25/2025

Artiva (ARTV) Q2 Loss Widens 19.7%

  • Artiva Biotherapeutics (ARTV -6.82%), a clinical-stage biotechnology company pioneering allogeneic natural killer (NK) cell therapies for autoimmune diseases, released its financial results for the second quarter on August 6, 2025. The earnings showed a net loss per share of $(0.87), which was wider than the consensus estimate of $(0.81).
    08/06/2025
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Artiva Biotherapeutics, Inc. Common Stock (ARTV) can hold. Click on Rating Page for detail.

The price of Artiva Biotherapeutics, Inc. Common Stock (ARTV) is 2.57 and it was updated on 2025-09-12 11:00:31.

Currently Artiva Biotherapeutics, Inc. Common Stock (ARTV) is in undervalued.

News
    
News

Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

  • First patient treated in company-sponsored global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies, and systemic sclerosis Continued execution and enrollment progress with over a dozen patients treated with AlloNK + mAb across over a dozen sites in company-sponsored and investigator-initiated clinical trials in autoimmune diseases Initial safety, translational data, and lead indication selection for AlloNK in autoimmune diseases to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Cash runway into Q2 2027, with cash, cash equivalents, and investments of $142.4 million as of June 30, 2025 SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the second quarter ended June 30, 2025, and highlighted recent progress. “We are making meaningful progress across our ongoing clinical trials exploring AlloNK® in autoimmune disease.
    Wed, Aug. 06, 2025

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

  • SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 9:20 a.m. EDT.
    Wed, May. 28, 2025

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

  • 64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL
    Tue, May. 13, 2025

Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

  • IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis
    Thu, May. 08, 2025

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

  • Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK® + rituximab for the treatment of B-cell driven diseases in a community setting
    Mon, Apr. 28, 2025
SEC Filings
SEC Filings

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - EFFECT

  • SEC Filings
  • 08/18/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 4

  • SEC Filings
  • 08/18/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - S-8

  • SEC Filings
  • 08/06/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - S-3

  • SEC Filings
  • 08/06/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 8-K - Current report

  • SEC Filings
  • 08/06/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/06/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - SCHEDULE 13G/A

  • SEC Filings
  • 07/16/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 4

  • SEC Filings
  • 06/26/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 8-K - Current report

  • SEC Filings
  • 06/25/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - SCHEDULE 13G/A

  • SEC Filings
  • 05/15/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 8-K - Current report

  • SEC Filings
  • 05/08/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/08/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - DEFA14A

  • SEC Filings
  • 04/29/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - DEF 14A

  • SEC Filings
  • 04/29/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - ARS

  • SEC Filings
  • 04/29/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 4

  • SEC Filings
  • 04/25/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 3

  • SEC Filings
  • 04/25/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - SCHEDULE 13G

  • SEC Filings
  • 04/23/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 8-K - Current report

  • SEC Filings
  • 03/24/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 10-K - Current report

  • SEC Filings
  • 03/24/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 4

  • SEC Filings
  • 03/07/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 4

  • SEC Filings
  • 02/28/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 8-K - Current report

  • SEC Filings
  • 01/29/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 4

  • SEC Filings
  • 01/29/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 3

  • SEC Filings
  • 01/29/2025

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - SC 13G/A

  • SEC Filings
  • 11/14/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 8-K - Current report

  • SEC Filings
  • 11/12/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/12/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 8-K - Current report

  • SEC Filings
  • 10/22/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 4

  • SEC Filings
  • 10/22/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 3

  • SEC Filings
  • 10/22/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 4

  • SEC Filings
  • 09/13/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - SC 13D/A

  • SEC Filings
  • 09/03/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 8-K - Current report

  • SEC Filings
  • 08/29/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/29/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - SC 13G

  • SEC Filings
  • 08/01/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - SC 13D

  • SEC Filings
  • 07/29/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 4

  • SEC Filings
  • 07/24/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - S-8

  • SEC Filings
  • 07/22/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 8-K - Current report

  • SEC Filings
  • 07/22/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 424B4

  • SEC Filings
  • 07/22/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 4

  • SEC Filings
  • 07/22/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - SEC STAFF LETTER

  • SEC Filings
  • 07/19/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - S-1MEF

  • SEC Filings
  • 07/18/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - EFFECT

  • SEC Filings
  • 07/18/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - CERT

  • SEC Filings
  • 07/18/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 3

  • SEC Filings
  • 07/18/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - CORRESP

  • SEC Filings
  • 07/16/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - 8-A12B

  • SEC Filings
  • 07/16/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - S-1/A

  • SEC Filings
  • 07/15/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - CORRESP

  • SEC Filings
  • 07/05/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - S-1

  • SEC Filings
  • 06/28/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - CORRESP

  • SEC Filings
  • 06/28/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - UPLOAD

  • SEC Filings
  • 06/21/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - DRS/A

  • SEC Filings
  • 06/10/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - DRSLTR

  • SEC Filings
  • 06/07/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - SEC STAFF LETTER

  • SEC Filings
  • 05/31/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - UPLOAD

  • SEC Filings
  • 05/30/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - DRS

  • SEC Filings
  • 05/03/2024

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - RW

  • SEC Filings
  • 11/01/2022

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - S-1/A

  • SEC Filings
  • 06/06/2022

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - S-1/A

  • SEC Filings
  • 03/07/2022

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - S-1/A

  • SEC Filings
  • 01/21/2022

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - S-1/A

  • SEC Filings
  • 12/16/2021

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - S-1

  • SEC Filings
  • 04/08/2021

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - D

  • SEC Filings
  • 04/05/2021

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - DRS

  • SEC Filings
  • 03/02/2021

Artiva Biotherapeutics, Inc. Common Stock (ARTV) - D

  • SEC Filings
  • 07/10/2020
Press Releases
StockPrice Release

Artiva biotherapeutics to participate in the cantor global healthcare conference 2025

  • 08/25/2025

Artiva biotherapeutics reports second quarter 2025 financial results, recent business highlights

  • 08/06/2025

Artiva biotherapeutics to participate in the jefferies global healthcare conference

  • 05/28/2025

Artiva biotherapeutics announces longer-term phase 1/2 data demonstrating prolonged durability for allonk® in combination with rituximab in patients with b-cell-non-hodgkin lymphoma at the asgct 28th annual meeting

  • 05/13/2025

Artiva biotherapeutics reports first quarter 2025 financial results, recent business highlights

  • 05/08/2025

Artiva biotherapeutics to present longer-term phase 1/2 data for allonk® in combination with rituximab in patients with b-cell-non-hodgkin lymphoma at the asgct 28th annual meeting

  • 04/28/2025

Artiva biotherapeutics appoints subhashis banerjee, m.d., as chief medical officer

  • 04/08/2025

Artiva biotherapeutics to participate in the 24th annual needham virtual healthcare conference

  • 03/31/2025

Artiva biotherapeutics reports full year 2024 financial results and recent business highlights

  • 03/24/2025

Artiva biotherapeutics to participate in the td cowen 45th annual health care conference

  • 02/20/2025

Artiva biotherapeutics expands board of directors with appointment of dan baker, m.d.

  • 01/29/2025

Artiva biotherapeutics reports third quarter 2024 financial results and recent business highlights

  • 11/12/2024

Artiva biotherapeutics to participate in the jefferies london healthcare conference

  • 11/11/2024

Artiva biotherapeutics appoints alison moore, ph.d., to its board of directors

  • 10/22/2024

Artiva biotherapeutics to participate in the 2024 cantor fitzgerald global healthcare conference

  • 09/10/2024

Artiva biotherapeutics reports second quarter 2024 financial results and recent business highlights

  • 08/29/2024
More Headlines
News

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

  • Dr. Banerjee's appointment culminates Artiva's efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapy Dr. Banerjee's appointment culminates Artiva's efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapy
  • 04/08/2025

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

  • SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 11:00 a.m. EDT.
  • 03/31/2025

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

  • Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical conference in 2025 Strengthened key leadership with cell therapy and autoimmune expertise across organization Robust balance sheet with cash, cash equivalents and investments of $185.4 million as of December 31, 2024, is expected to fund operations at least through end of 2026 SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the full year ended December 31, 2024, and highlighted recent progress. “2024 was a transformational year for Artiva including initiating dosing of AlloNK® in patients with autoimmune disease across our trials, a successful initial public offering strengthening our balance sheet, and expanding key leadership across the organization with expertise in cell therapy and autoimmune disease,” said Fred Aslan, M.D.
  • 03/24/2025

Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

  • SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 2:30 p.m. EST, in Boston, MA.
  • 02/20/2025

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

  • SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker brings over two decades of drug development experience in the pharmaceutical industry. He is currently the interim Chief Development Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at Johnson & Johnson (Janssen/Centocor) (J & J) most recently as the Vice President of Immunology R&D.
  • 01/29/2025

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

  • Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases
  • 11/12/2024

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

  • SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 3:30 p.m. GMT, in London, UK.
  • 11/11/2024

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

  • SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors.
  • 10/22/2024

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

  • SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 18, 2024, at 8:00 a.m.
  • 09/10/2024

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

  • Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK® exploring multiple autoimmune indications Treated first patient in Artiva sponsored Phase 1/1b trial in patients with class III or IV lupus nephritis (LN) and expanded trial to include patients with systemic lupus erythematosus (SLE) without kidney involvement SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent progress. “Artiva is at an inflection point as we advance AlloNK® in clinical development across multiple autoimmune indications and transition to a publicly traded company,” said Fred Aslan, M.D.
  • 08/29/2024

This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment

  • Artiva has two-bagger potential in the eyes of multiple Wall Street analysts. Its cell therapies could provide a much more efficient treatment of autoimmune diseases.
  • 08/29/2024

Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch

  • In July, Artiva Biotherapeutics, Inc. ARTV priced its upsized initial public offering of 13.92 million shares at $12.00 per share, with gross proceeds of approximately $167.0 million.
  • 08/13/2024

Insider Buying in These 2 IPOs Is Huge, Plus Financial CEOs Pick Up Shares

  • 24/7 Wall St. Insights In the past week or so, initial public offerings at a biotech and an investment management firm attracted huge insider buying.
  • 07/28/2024

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

  • A handful of IPOs priced this past week, led by three sizable names. One large issuer joined both the pipeline and the calendar - Chile-based LATAM Airlines Group. Six IPOs are scheduled to list in the week ahead and are set to raise a combined $5.1 billion, the most for any week so far this year. One SPAC is also set to debut.
  • 07/20/2024
Unlock
ARTV Ratings Summary
ARTV Quant Ranking